Exelixis

FDA Accepts Exelixis' NDA for Colorectal Cancer Combo, Boosting Valuation Focus

伊克力西斯

Exelixis's 15min chart triggers Bollinger Bands Narrowing and KDJ Death Cross.

Exelixis: Barclays Keeps Equal-Weight Rating, Raises PT to $44 from $41.

Exelixis's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.

Exelixis:HC Wainwright Raises Buy Rating, PT to $52 from $52

Catalyst<ul> <li>Most analysts rate EXEL Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 1 bullish).</li> <li>Fund flow overall trend is negative with large and extra-large orders showing outflows.</li></ul>

Key Factors

FDA accepted Exelixis' New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

EXEL News